Home › Chronic Lymphocytic Leukemia › California
Pag-aaral pangklinika para sa Chronic Lymphocytic Leukemia sa California
34 pag-aaral para sa Chronic Lymphocytic Leukemia ang naghahanap ng mga kalahok sa mga site sa California.
Mga Lungsod sa California
- Baldwin Park16 pag-aaral
- San Diego10 pag-aaral
- Los Angeles8 pag-aaral
- Mountain View7 pag-aaral
- Orange6 pag-aaral
- Irvine6 pag-aaral
- Long Beach4 pag-aaral
- San Francisco4 pag-aaral
- Anaheim3 pag-aaral
- Burbank3 pag-aaral
- Sacramento3 pag-aaral
- Santa Monica3 pag-aaral
Opisyal na teksto ng pag-aaral (English)
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Kaiser Permanente-Anaheim, Anaheim
- Kaiser Permanente-Baldwin Park, Baldwin Park
- Kaiser Permanente-Bellflower, Bellflower
- at 28 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT04269902A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Research Site, La Jolla
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06542250A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 115, Huntington Park
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Uci Health Laguna Hills, Laguna Hills
- Chao Family Comprehensive Cancer Center, Orange
- Stanford Cancer Institute, Palo Alto
- at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06943872A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
- City of Hope National Medical Center, Duarte
- Chao Family Comprehensive Cancer Center, Orange
- Stanford Cancer Institute, Palo Alto
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07277231A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
- Stanford Medicine, Palo Alto
- UCLA Santa Monica Cancer Care, Santa Monica
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Kaiser Permanente Southern California, Irvine
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla
- Cancer and Blood Specialty Clinic, Los Alamitos
- at 8 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06973187A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- UCLA Department of Medicine Hematologyoncology, Los Angeles
- Scripps Prebys Cancer Center, San Diego
- Pih Health Whittier Hospital, Whittier
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06846671A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- MemorialCare Health System - Long Beach Medical Center ( Site 5421), Long Beach
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Moores Cancer Center ( Site 0003), La Jolla
- Care Access - South Pasadena ( Site 0070), Pasadena
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- UC Irvine, Orange
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- City of Hope, Duarte
- Cedars-Sinai Medical Center, Los Angeles
- Scripps Health, San Diego
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07221500Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
- City of Hope Comprehensive Cancer Center, Duarte
- City of Hope at Irvine Lennar, Irvine
- University of California Davis Comprehensive Cancer Center, Sacramento
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 11, 2026 · NCT07061951Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- City of Hope National Medical Center, Duarte
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT04588922Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Kaiser Permanente-Anaheim, Anaheim
- Kaiser Permanente-Baldwin Park, Baldwin Park
- Kaiser Permanente-Bellflower, Bellflower
- at 12 pa
Nagre-recruitPhase 3
Edad 65 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande
- PCR Oncology, Arroyo Grande
- AIS Cancer Center at San Joaquin Community Hospital, Bakersfield
- at 20 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT05334069A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- City of Hope, Duarte
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT06528301A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Pacific Cancer Medical Center, Inc, Anaheim
- TOI Clinical Research, Cerritos
- Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05254743Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- City of Hope, Duarte
- Valkyrie Clinical Trials, Los Angeles
Nagre-recruitPhase 1/2
Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579A Long-term Extension Study of PCI-32765 (Ibrutinib)
- St. Joseph Hospital Center for Cancer Prevention and Treatment, Orange
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT01804686A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT07020533A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
- University of California, San Francisco, San Francisco
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 2, 2026 · NCT05131022Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- University of California, San Francisco, San Francisco
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 22, 2026 · NCT04545762A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- City of Hope National Medical Center, Duarte
- City of Hope National Medical Center, Irvine
- Palo Alto Medical Foundation Research Institute (PAMFRI), Palo Alto
- at 1 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 19, 2026 · NCT06588478Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- City of Hope Medical Center, Duarte
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 20, 2026 · NCT06859008The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- City of Hope, Duarte
- Los Angeles Cancer Network, Los Angeles
- UCLA Medical Center of Hematology/Oncology, Los Angeles
- at 1 pa
Nagre-recruitPhase 1/2
Edad 12 hanggang 95 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT04329728A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- UCSF FRESNO/Community Cancer Institute /ID# 270874, Clovis
- Valkyrie Clinical Trials /ID# 268151, Los Angeles
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 9, 2026 · NCT06428019Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Stanford Cancer Institute Palo Alto, Palo Alto
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 25, 2026 · NCT05388006A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- City of Hope, Duarte
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 20, 2026 · NCT04830137Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
- City of Hope at Long Beach Elm, Long Beach
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT07218510CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- City of Hope Medical Center, Duarte
Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Mar 10, 2026 · NCT06059391Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Moores Cancer Center at UC San Diego /ID# 230157, La Jolla
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 9, 2026 · NCT04895436AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- UC Irvine Health, Orange
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 10, 2025 · NCT05602363A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- San Francisco VA Medical Center, San Francisco, CA, San Francisco
Nagre-recruitPhase 2
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Okt 14, 2025 · NCT06520098Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.